Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive June 1, 2011	2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead.
Pharmaceutical Executive October 1, 2005 Jeffrey D. Abbey	Considering Intangibles Biotech partnerships among scientists, academic institutions, and pharma companies provide many challenges, including identifying the right partners, developing strong relationships to overcome hurdles, and dealing with cultural differences in an increasingly global market.
Pharmaceutical Executive July 1, 2012	Emerging Pharma Leaders 2012 Meet 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history by doing better with less while tapping new opportunities from science and technology to build competitive scale?
Pharmaceutical Executive June 1, 2011	Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity?
Pharmaceutical Executive October 1, 2005 Fine & Meyer	An 11-Step Program to Navigating Partnerships Commercial partnerships are an effective way to differentiate both research institutes and biotech companies. It is critical to recognize that while financial return is the primary driver of a commercial partnership, the cultural fit can sustain its success.
Pharmaceutical Executive December 1, 2008 Walter Armstrong	The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future.
Bank Director 2nd Quarter 2009 Deborah Scally	Outlook for M&A: 2009 Interestingly, for some banks, M&A will be a viable -- even attractive -- strategic option.
Pharmaceutical Executive June 1, 2012	2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead.
Pharmaceutical Executive July 10, 2014 William Looney	Pharm Exec's 2014 Dealmakers Outlook As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead.
Pharmaceutical Executive January 1, 2009 Stan Bernard	Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms.
Pharmaceutical Executive October 1, 2005 Joseph S. Dillon	Risks and Rewards: How to Protect the Hand You're Dealt Like each bet at the gaming table, the wagers and payoffs of pharma deals must be condsidered on their own merits, using careful due diligence to achieve a beneficial deal structure.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Pharmaceutical Executive October 1, 2005 Mark J. Ahn	It's All Academic: Biotechs Looking to Universities Pharmaceuticals and academic institutions are forming alliances at an increasing rate to exploit the promise of emerging biological insights.
Pharmaceutical Executive May 1, 2009	The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game.
The Motley Fool June 7, 2006 Stephen D. Simpson	Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week.
Knowledge@Wharton	The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope...
Pharmaceutical Executive June 1, 2007 Michael Goodman	A Very Specialty Moment Big Pharma is on a shopping spree for biologics and other specialty products. It has the money to buy them. But does it have the mojo to develop and market them successfully - or will the mid-size biopharmas make their big move?
Pharmaceutical Executive January 1, 2011	The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs
Pharmaceutical Executive April 1, 2007 Walter Armstrong	Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom.
U.S. Banker March 2003 Michael Sisk	Ranking the Top M&A Advisors Competition is fierce in the down economy. Sandler O'Neill did 24 deals, but Goldman's two deals were far larger. Boards of Directors are seeking out investment bankers earlier when thinking about a merger and demanding more from them.
Pharmaceutical Executive August 1, 2012	Sunny Outlook for Biopharm 2020? Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020. Just watch out for the harsh light of complacency.
Pharmaceutical Executive April 1, 2014 William Looney	The Trials of Commerce Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.
Pharmaceutical Executive May 1, 2005	Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short.
The Motley Fool February 9, 2009 Robert Steyer	Just Say No to Drug Company Mergers There are some reasons to make a big-pharma deal. But there are as many, if not more, reasons to let these companies pursue smaller deals and collaborations rather than become just another part of a hyphenated corporate name.
The Motley Fool February 25, 2004 Brian Gorman	Merck's Slow and Steady The big pharma's cautious approach could pay off in the industry.
Pharmaceutical Executive September 1, 2008 Walter Armstrong	The M&A Numbers Young & Partners crunches pharma's filings for the first half of '08.
Pharmaceutical Executive February 1, 2007 Ben Bonifant et al.	Driven to License The competition for innovative biotech products is intense, giving rise to an unprecedented diversity of partnering strategies and an equally unprecedented convergence of small-molecule drugs and biologics in company portfolios. Licensings are shaping up as the year's big deal.
Pharmaceutical Executive July 3, 2007	Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future.
Pharmaceutical Executive February 1, 2012 Wilcox et al.	Sales Force Survey: Still Too Much Business as Usual? In the global battle for market share, the ability to adapt and mobilize your human assets around a responsive commercial model is a key variable of success.
Pharmaceutical Executive August 1, 2005 Jill Wechsler	Washington Report: Treating Patents It may seem unusual that a court ruling challenging patent protections is considered a victory for Big Pharma. But the decision was supported by pharmaceutical companies, along with the Justice Department, as a way to spur biomedical research and new-drug development.
Pharmaceutical Executive November 1, 2011	Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk.
Pharmaceutical Executive January 1, 2012 William Looney	Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Pharmaceutical Executive September 1, 2010	Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development.
Pharmaceutical Executive September 1, 2008 Zhu Shen	Unleash the Dragon Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital.
The Motley Fool August 29, 2008 Brian Lawler	Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity?
Pharmaceutical Executive March 1, 2007	Finance: Q&A with Annette Grimaldi It's now more lucrative for a small pharmaceutical company to sell than to go public. Here is how the past year has shaped up - and what might be next on the horizon.
Bio-IT World December 10, 2002 Malorye Branca	The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D.
Pharmaceutical Executive January 1, 2012 Jill Wechsler	New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation.
Pharmaceutical Executive January 1, 2009 Walter Armstrong	Up in the Air If pharma execs start upping their consumption of antihypertensives and anxiolytics (all branded, of course) in the months to come, it won't be a huge surprise. The industry faces a truly unprecedented number of political and policy challenges.
CFO May 8, 2006 Don Durfee	Try Before You Buy Companies are using alliances to take the risk out of acquisitions.
Pharmaceutical Executive February 1, 2006 Ron Feemster	Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Pharmaceutical Executive September 1, 2006	Finance: Good Alternatives With more ways to raise cash, biotechs with hot products can extend their independence.
Chemistry World February 2008 Nuala Moran	The Chemistry of Private Equity Private equity has transformed the chemicals industry, but can it play the same role in high-risk R&D driven companies?
Pharmaceutical Executive March 1, 2009 Brittany Agro	The New Sales Force The arms race is over, and it's time to reinvent pharma sales. Here's what forward-looking companies are experimenting with, and how it's working.
Pharmaceutical Executive January 1, 2007 Walter Armstrong	Forecast 2007: At Sea In times of crisis, it's harder than ever to take the long view. The healing arts may be as old as humankind, but the business of pharma is still in its infancy.
BusinessWeek September 12, 2005 David Henry	Speed Bumps For Dealmakers Proposed rule changes may force corporate buyers to bare more detail -- and take more lumps that could hurt their results and make earnings more volatile. Dealmaking may be less fun in the future. But investors should get a much clearer view of what it's costing them.
Managed Care February 2002 Ira Studin	Reframing the Pharmaceutical Manufacturer/Health Plan Relationship in Managed Care It is suggested that health plans address "total cost-of-care savings" in their budget process, and the pharmaceutical manufacturers establish a "consultative service function" in their managed care divisions...
Bank Technology News September 2008 Glen Fest	Budgets Hold Steady in Downturn A new study shows plenty of healthy signs for continued IT investments at banks, particularly in automation, e-channel investments and analytics infrastructure.
Pharmaceutical Executive December 1, 2006 Ragnar Lofstedt	Back Page: The Post-Trust World People no longer put their faith in industry or regulators. What can we do about that? A good start would be understanding the human side of risk.